Roche has again extended the offering period of its previously announced tender offer to purchase all of the outstanding shares of common stock of Spark Therapeutics Inc. for $114.50 per share.
The offer, which was previously scheduled to expire at 5 p.m., EST on Tuesday, September 3, 2019, has been extended until 5 p.m. EST on Tuesday, October 1, 2019, unless it is extended further.
The offer was extended to provide additional time for the U.S. Federal Trade Commission and the UK Competition and Markets Authority to complete their reviews of the acquisition.
Citibank N.A., the depository for the offer, has advised Roche that approximately 9,284,005 shares of Spark had been validly tendered and received, and not validly withdrawn, pursuant to the offer, representing approximately 24.1 percent of Spark’s outstanding shares.
